Comparing Daratumumab injection in thigh vs. abdomen for plasma cell disorders
Treatments studied
Part of Cancer clinical trials.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma (newly diagnosed or relapsed) or AL amyloidosis
- You are scheduled to start a treatment that includes daratumumab
- You have not had daratumumab before, or it's been more than 6 months since your last dose
- You are 18 years or older
- You are in fairly good health (able to care for yourself and up and about more than half the day)
- You are willing to come for weekly visits for 9 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called FreedomEDGE® that gives daratumumab under the skin instead of by an IV. It might make your monthly treatment faster and more comfortable.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.